Alzheimer's Disease (AD)
Conditions
Brief summary
Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \[68Ga\]-DOTA-HK-011 in neuroinflammation imaging of Alzheimer's disease.
Interventions
None listed
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Volunteer for the trial, with the patient or their legal guardian signing the informed consent form. * Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends. * The patient is diagnosed with Alzheimer's disease (AD), supported by a positive amyloid PET scan. * The patient has completed Tau PET scan.
Exclusion criteria
* Individuals with a history of allergy to drugs chemically or biologically similar to TSPO, a history of atopy, or currently suffering from allergic diseases. * Use of anti-inflammatory drugs, including corticosteroids and immunosuppressants, within the past 14 days, which may interfere with the accuracy of inflammation imaging. * Presence of other coexisting neurological diseases, such as stroke, Parkinson's disease, brain tumors, or mental disorders, including depressive disorder and schizophrenia. * Severe cardiac, pulmonary, hepatic, or renal dysfunction, or uncontrolled systemic diseases; 5. Presence of metal implants contraindicated for MRI, including but not limited to cardiac pacemakers, artificial heart valves, and metal stents. * Claustrophobia or inability to tolerate prolonged examinations. * Pregnant women (defined as those with a positive urine pregnancy test) or breastfeeding women. * Patients whose physical condition is unsuitable for radioactive tracer-based imaging examinations. * Other circumstances deemed unsuitable for participation in the trial by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax of lesion uptake value | 60min after administration |
Countries
China
Contacts
Primary ContactFeng Wang
Outcome results
None listed